4 unknown, 2 completed, 2 recruiting, 1 not yet recruiting. 9 Phase 2, 6 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Unknown 4, Completed 2, Recruiting 2, Not yet recruiting 1 |
| Phase 1 | 6 | Completed 2, Recruiting 2, Unknown 2 |
| Phase 3 | 1 | Unknown 1 |
Follow Relapse Leukemia: new trials by email Literature Review of Relapse Leukemia trials Research Report on Relapse Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Revumenib and Mezigdomide in People With Leukemia Revumenib, Mezigdomide - Leukemia, Acute Leukemia | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 52 | 2026-01-16 | 2026-10-20 |
| Efficacy and Safety of VAH as a Bridging Regimen to Allo-HCT in Relapsed/Refractory AML VAH - Relapse Leukemia | Phase 2 | Not yet recruiting | Ruijin Hospital | 44 | 2025-08-01 | 2025-07-29 |
| Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT Phase 1 Dose Level 1, Phase 1 Dose Level 2, Phase 1 Dose Level 3 - Leukemia, High Risk Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Children's Hospital of Philadelphia | 100 | 2025-03-21 | 2026-04-15 |
| Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm CD123 targeted CAR-NK cells - Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 1 / Phase 2 | Completed | Chongqing Precision Biotech Co., Ltd | 5 | 2024-03-28 | 2026-08-05 |
| Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia chimeric antigen receptor T cell - Acute Myeloid Leukemia, Relapse Leukemia | Phase 1 / Phase 2 | Completed | Beijing Boren Hospital | 5 | 2021-04-08 | 2024-06-21 |
| Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia Allogeneic CD19 CAR-T cells - Relapse Leukemia, Refractory Leukemia | Phase 1 / Phase 2 | Unknown | Shenzhen University General Hospital | 20 | 2021-02-05 | 2021-12-20 |
| Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia Decitabine, mBU/CY and ATG, mBU/CY - Stem Cell Transplant Complications, Relapse Leukemia | Phase 2 / Phase 3 | Unknown | Peking University People's Hospital | 55 | 2018-12-01 | 2019-05-29 |
| Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) GLIDE - Hematologic Cancer, Relapse Leukemia | Phase 1 / Phase 2 | Unknown | Ciusss de L'Est de l'Île de Montréal | 20 | 2017-02-06 | 2017-12-06 |
| Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia Cladribine, G-CSF, Aclarubicin - Acute Myeloid Leukemia, Relapse Leukemia | Phase 2 | Unknown | Sun Yat-sen University | 48 | 2016-01-01 | 2019-08-20 |
Leukemia (5) · Leukemia, Myeloid, Acute (5) · Lymphoma, Non-Hodgkin (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Anemia, Refractory, with Excess of Blasts (1) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Bone Marrow Failure Disorders (1) · Congenital Bone Marrow Failure Syndromes (1) · Hematologic Neoplasms (1) · Hemoglobinopathies (1) · Hodgkin Disease (1) · Immunologic Deficiency Syndromes (1) · Leukemia, Biphenotypic, Acute (1) · Metabolism, Inborn Errors (1) · Multiple Myeloma (1)
Hematologic Diseases (8) · Hemic and Lymphatic Diseases (8) · Neoplasms (8) · Neoplasms by Histologic Type (8) · Leukemia, Myeloid (5) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Leukemia (3) · Lymphatic Diseases (3) · Lymphoma (3) · Lymphoproliferative Disorders (3) · Bone Marrow Diseases (2) · Leukemia, Lymphoid (2) · Neoplasms by Site (2) · Anemia (1)
Aclarubicin (1) · Cladribine (1) · Clinical Trials, Phase I as Topic (1) · Cytarabine (1) · Decitabine (1) · Granulocyte Colony-Stimulating Factor (1) · aclacinomycins (1) · revumenib (1)
Beijing Boren Hospital (1) · Children's Hospital of Philadelphia (1) · Chongqing Precision Biotech Co., Ltd (1) · Ciusss de L'Est de l'Île de Montréal (1) · Memorial Sloan Kettering Cancer Center (1) · Peking University People's Hospital (1) · Ruijin Hospital (1) · Shenzhen University General Hospital (1) · Sun Yat-sen University (1)
China (6) · United States (2) · Canada (1)
Denis-Claude Roy, MD PhD (1) · Jia Wei, M.D (1) · Jing Pan, MD/PhD (1) · Kuo-Kai Chin, MD (1) · Li Yu, Dr (1) · Liang Wang, M.D. (1) · Silvy Lachance, MD (1) · Timothy Olson, MD, PhD (1) · Xiao-Jun Huang (1) · Xiaoxia HU (1)